Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect
Foo, C. S.; Abdelnabi, R.; Kaptein, S. J. F.; Zhang, X.; ter Horst, S.; Mols, R.; Delang, L.; Rocha-Pereira, J.; Coelmont, L.; Leyssen, P.; Dallmeier, K.; Vergote, V.; Heylen, E.; Vangeel, L.; Chatterjee, A. K.; Annaert, P.; Augustijns, P.; De Jonghe, S.; Jochmans, D.; Weynand, B.; Neyts, J.
Show abstract
In response to the ongoing COVID-19 pandemic, repurposing of drugs for the treatment of SARS-CoV-2 infections is being explored. The HIV protease inhibitor Nelfinavir, widely prescribed in combination with other HIV inhibitors, has been shown to inhibit in vitro SARS-CoV-2 replication. We here report on the effect of Nelfinavir in the Syrian hamster SARS-CoV-2 infection model. Although treatment of infected hamsters with either 15 or 50 mg/kg BID Nelfinavir [for four consecutive days, initiated on the day of infection] does not reduce viral RNA loads nor infectious virus titres in the lungs compared to the vehicle control, the drug reduced virus-induced lung pathology to nearly the baseline scores of healthy animals. A substantial interstitial infiltration of neutrophils is observed in the lungs of treated (both infected and uninfected) animals. The protective effect of Nelfinavir on SARS-CoV-2-induced lung pathology (at doses that are well tolerated and that result in exposures nearing those observed in HIV-infected patients) may lay the foundation for clinical studies with this widely used drug.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity 95%
- Compound FC-10696 Inhibits Egress and Spread of Marburg Virus 95%
- Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice 94%
Similar papers in this journal
- The combination of GS-441524 (remdesivir) and ribavirin results in a potent antiviral effect against human parainfluenza virus 3 infection in human airway epithelial cell cultures and in a mouse infection model 95%
- Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants. 94%
- Effect of exportin 1/XPO1 nuclear export pathway inhibition on coronavirus replication. 94%
Similar papers in this journal
- Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19 94%
- Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice 94%
- Inhibitors of anti-apoptotic Bcl-2 family proteins exhibit potent and broad-spectrum anti-mammarenavirus activity via cell cycle arrest at G0/G1 phase 94%
Similar papers in this journal
Similar papers in this journal
- Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants 94%
- Metal Coordinating Inhibitors of Rift Valley Fever virus Replication 92%
- Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.